Lemelin A, Zarba M, Takemura K, Wells JC, Chehade REH, Donskov F, Porta C, De Velasco G, Davis ID, Wood LA, Pal SK, Hansen AR, Tran B, Bjarnason GA, Li H, Kanesvaran R, Powles T, McKay RR, Choueiri TK, Heng DYC. Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC). Clinical Genitourinary Cancer. 2026;24(1):10.1016/j.clgc.2025.102484
Moody SC, Fietz D, Nathaniel B, Frydenberg M, Tran B, Schuppe H, Loveland KL. Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours. Andrology. 2026;14(1):10.1111/andr.70100
Chen DC, Buteau JP, Papa N, Akhurst T, Alipour R, Bollampally N, Cardin A, Eifer M, Casanueva Eliceiry S, Jackson P, Jewell K, Kashyap R, Kong G, Kostos L, Ravi Kumar A, McIntosh L, Medhurst E, Saghebi J, Sandhu S, Murphy DG, Tran B, Azad AA, Hofman MS. Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.Journal of Nuclear Medicine. 2025;66(12):10.2967/jnumed.125.270804
Anton A, Joung JY, Han H, Kanesvaran R, Weickhardt AJ, Wong SSL, Azad A, Shapiro J, Brown S, Goh JCH, Parente P, Oliveira N, Torres J, Liow ECH, Smith A, Steer C, Gibbs P, Tran B. 503P Treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), real-world adoption of combination therapies in Australia and Asia. Annals of Oncology. 2025;36:10.1016/j.annonc.2025.10.398
Bainomugisa CK, Dasgupta P, Cameron JK, Tran B, Cramb SM, Baade PD. Spatial patterns of testicular cancer diagnosis in Australia, 2010-2019. Spatial and Spatio-temporal Epidemiology. 2025;55:10.1016/j.sste.2025.100745
Shahnam A, Hitchen N, Manoharan S, John T, Mileshkin L, Solomon B, Sandhu S, Luen SJ, Desai J, Tran B. Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies. Journal of Geriatric Oncology. 2025;16(8):10.1016/j.jgo.2025.102721
Kostos L, Buteau JP, Xie J, Cardin A, Akhurst T, Alipour R, Au L, Chan J, Chin KY, Emmerson B, Furic L, Garcia Q, Hamilton AJ, Haskali MB, Jackson PA, Kashyap RK, Kong G, MacFarlane L, Murphy DG, Parker BS, Ravi Kumar AS, Saghebi J, Wang Y, Tran B, Azad AA, Hofman MS. Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial. The Lancet Oncology. 2025;26(11):10.1016/s1470-2045(25)00559-5
Daneshmand S, Zaucha R, Catto JWF, Tran B, Master V, Lotan Y, Pignot G, Tubaro A, Shimizu N, Vasdev N, Lee EK, Procopio G, Galanternik F, Crow L, Deprince K, Naini V, Triantos S, Baig M, Zhu W, Maranchie JK. Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. European Urology. 2025;:10.1016/j.eururo.2025.09.4152
Eid M, Semaan K, Xie W, Chehade REH, Ascione L, Maj D, Zarba M, Wells JC, Wood L, Tran B, Angel M, Pal SK, Lee J-L, Takemura K, Kollmannsberger CK, Templeton AJ, Bjarnason GA, Ruiz JM, Heng D, Choueiri TK. 50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study. The Oncologist. 2025;30(Supplement_2):10.1093/oncolo/oyaf276.051
Grande E, Bellmunt J, Hussain SA, Al Mansour MM, Bamias A, Barthélémy P, Benjamin DJ, Blais N, Bourlon MT, Castellano D, Danchaivijitr P, Lazzaro MF, Giannatempo P, Guerrero-Ramos F, Iacovelli R, Ivanyi P, Jung EH, Kanesvaran R, Manneh R, Marinho JC, Matsubara N, Merseburger AS, Mukherji D, Park CH, Tran B, da Trindade KM, Ürün Y, Kamat AM, Birtle AJ. Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey. The Oncologist. 2025;30(10):10.1093/oncolo/oyaf333
